Simple Summary Innate immune natural killer (NK) cells are capable of killing metastatic
cancer cells without activation by antigen-presenting cells beforehand. The cytotoxic effects …

Natural killer (NK) cell-based immunotherapies are attracting increasing interest in the field
of cancer treatment. Early clinical trials have shown promising outcomes, alongside …

Simple Summary Natural Killer (NK) cells play a major role in cancer immunotherapy based
on tumor-targeting mAbs. NK cell-mediated tumor cell killing and cytokine secretion are …

Multiple myeloma (MM) is a hematological malignancy characterized by clonal proliferation
of plasma cells. Although therapeutic advances have been made to improve clinical …

The CD38-targeting antibody daratumumab has marked activity in multiple myeloma (MM).
Natural killer (NK) cells play an important role during daratumumab therapy by mediating …

In a short time, single-cell platforms have become the norm in many fields of research,
including multiple myeloma (MM). In fact, the large amount of cellular heterogeneity in MM …

Multiple myeloma (MM) is the second most common hematological malignancy and is
attributed to monoclonal proliferation of plasma cells in the bone marrow. Cancer cells …

Natural killer (NK) cells belong to the early responder group against cancerous cells and
viral infection. Emerging evidence reveals that distinct metabolic reprogramming occurs …

Immune cells can actively regulate tumors or inflammatory sites and have good
biocompatibility and safety. Currently, they are one of the most promising candidates for …

CD38 and B-cell maturation antigens (BCMAs) are prevalently expressed on neoplastic
plasma cells in multiple myeloma (MM), making them ideal therapeutic targets. Anti-CD38 …